1. HPV, Biomarkers and HIV
How do HPV E6/E7 promote carcinogenesis and p16 overexpression?
High-risk HPV E6 promotes degradation of the tumour suppressor p53, while E7 inactivates RB (retinoblastoma protein). Loss of RB activity releases E2F and drives uncontrolled cell-cycle progression. This disruption of the RB pathway results in overexpression of p16, making p16 a useful surrogate marker of HPV-driven disease.
Clinical significance of HPV-16 and p16 positivity:
HPV-16 is the most important high-risk HPV type associated with anal SCC. HPV-positive/p16-positive tumours generally have a better prognosis and greater treatment responsiveness than HPV-negative tumours, although treatment is still based primarily on stage rather than HPV status.
How does well-controlled HIV affect treatment?
With virologic suppression and CD4 420 cells/µL, this patient can generally receive standard chemoradiotherapy. Modern ART has substantially improved outcomes, and HIV infection alone should not be a reason to withhold curative treatment. Careful monitoring for infection, marrow suppression, skin toxicity and treatment interruptions is important.
2. Definitive Chemoradiotherapy
Why chemoradiotherapy rather than initial surgery?
Definitive chemoradiotherapy is the standard treatment for most non-metastatic anal SCC because it can achieve high rates of local control and sphincter preservation, avoiding the permanent colostomy associated with primary APR.
5-FU + MMC versus cisplatin-based regimens:
5-FU + mitomycin C (MMC) remains the standard concurrent chemotherapy regimen. Trials such as ACT II showed that replacing MMC with cisplatin did not improve outcomes sufficiently to replace MMC as standard treatment.
Role of IMRT:
IMRT allows more precise radiation delivery while reducing radiation exposure to surrounding normal tissues. It can reduce acute gastrointestinal, skin and hematologic toxicity, and reduce treatment interruptions while maintaining excellent tumour control.
3. Response Assessment and Salvage Surgery
How should response be assessed?
Assessment should include clinical examination/DRE, anoscopy or proctoscopy and imaging when indicated. PET/CT or pelvic MRI can be useful when residual disease is suspected, but imaging findings should be interpreted alongside clinical examination.
What is a clinical complete response (cCR), and when should it be assessed?
A cCR means no clinically detectable residual tumour, with resolution of the mass, ulceration and other suspicious findings. Response should not be assessed too early because regression can continue for several months. Initial assessment is commonly performed around 8–12 weeks after treatment, with continued surveillance if there is ongoing regression.
When is salvage APR indicated?
Salvage APR is considered for biopsy-proven persistent disease that does not respond to chemoradiotherapy or biopsy-proven local recurrence, particularly when there is no distant metastatic disease and complete resection is feasible.
4. Resource-Constrained Setting
What if radiotherapy access or MMC is limited?
Treatment should be planned to minimize interruptions, because prolonged overall treatment time can compromise local control. Patients should ideally receive uninterrupted definitive radiation. If MMC is unavailable or contraindicated, a fluoropyrimidine with an alternative radiosensitizing regimen may be considered according to available evidence and specialist guidance.
Evidence for capecitabine-based treatment:
Oral capecitabine can replace infusional 5-FU during radiotherapy and has been studied with MMC. It avoids the need for a central venous catheter and continuous infusion, potentially making it more practical in resource-constrained settings. Evidence supports it as a reasonable alternative when appropriately dosed and monitored.
Reducing financial and logistical barriers:
- Coordinate CT/MRI, chemotherapy and radiotherapy appointments to minimize travel.
- Use IMRT where available to reduce toxicity and treatment interruptions.
- Consider oral capecitabine where affordable and appropriate.
- Provide patients with a clear treatment-cost estimate before starting.
- Coordinate ART with oncology treatment rather than interrupting HIV therapy.
- Establish mechanisms for rapid management of toxicity to prevent avoidable treatment breaks.
- Where possible, use social-support programmes or hospital assistance schemes for patients paying out of pocket.
For this patient, her suppressed HIV and CD4 count of 420 support proceeding with curative-intent standard chemoradiotherapy, with careful monitoring and strong emphasis on avoiding treatment interruptions.